ClinicalTrials.gg
Not yet recruitingNCT07438886Updated Feb 27, 2026

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

A Phase 1 interventional study of AL3818 Capsule and Itraconazole capsule in Healthy Volunteer, sponsored by Advenchen Laboratories Nanjing Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Advenchen Laboratories Nanjing Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.

Read the detailed description

This is a non-randomized, open-label, single-center, fixed-sequence drug-drug interaction (DDI) study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy adult subjects. Eligible subjects will receive a single dose of AL3818 alone and in combination with multiple doses of itraconazole or ticagrelor in different periods. Serial blood samples will be collected to determine plasma concentrations of AL3818. Safety and tolerability will be monitored throughout the study.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Advenchen Laboratories Nanjing Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject is eligible for enrollment in the study only if all of the following criteria are met:

  1. Male or female; aged between 18 and 45 years old (inclusive).
  2. Male subjects weight ≥50 kg, female subjects weight ≥45 kg, (BMI) between 19.0 and 26.0 kg/m2 , BMI= weight (kg)/height2 (m2 ) (inclusive).
  3. Physical examination, vital signs, 12-lead (ECG), laboratory tests (blood routine, urine routine, blood biochemistry, blood lipid, coagulation function and thyroid function, etc.) and chest X-ray at screening showed no abnormalities, and the clinical study doctor judged them qualified.
  4. The subject voluntarily signed a written form and is able to communicate well with the investigator.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria before screening will be excluded from the study:

  1. History of severe systemic diseases (including cardiovascular, digestive, urinary, respiratory, endocrine, immune, blood and lymphatic, skeletal/muscular, nervous and other system diseases), history of liver and kidney insufficiency, history of mental diseases, history of drug dependence, bleeding tendency (such as recent trauma, recent surgery, coagulation dysfunction, active or recent gastrointestinal bleeding), history of active pathological bleeding, history of intracranial hemorrhage, family history of hypertension;
  2. History of dysphagia or any gastrointestinal diseases affecting drug absorption, digestive system diseases (such as peptic ulcer, pancreatitis, colitis, etc.) within 3 months;
  3. Allergic to any component of the product (AL3818, itraconazole capsule, ticagrelor tablet) and its , with a history of drug or food allergy, or history of specific allergy (asthma, urticaria, eczema, etc.);
  4. Subjects who have had major diseases or major surgical procedures within 3 months prior to;
  5. Subjects who donated blood within 3 months, or planned to donate blood within the study period, or Subjects who had blood transfusion or blood loss ≥200 mL within 4 weeks;
  6. Participation in any clinical trial as a subject within 3 months;
  7. Subjects with drug abuse history within 5 years or drug use within 3 months or positive urine drug abuse screening at baseline;
  8. Anyone who has taken any prescription, over-the-counter, vitamin or herbal medicine within 2 weeks or 5 half-lives (whichever is longer);
  9. Any drug known to be an inhibitor or inducer of enzymes or a sensitive substrate (Appendix 4), any drug known to be a P-gp inhibitor or substrate (Appendix 5), any drug known to be a BCRP inhibitor or substrate (Appendix 6), or any drug known to cause a risk of torsades de pointes (TdP) (Appendix 7) within 4 weeks;
  10. Vaccination within 3 months or planned during this trial;
  11. Subjects with a history of bleeding and needle phobia, unable to tolerate intravenous indwelling needle injection;
  12. Subjects with neurological/psychiatric, respiratory, cardiovascular, digestive tract, blood and lymphatic system, endocrine, musculoskeletal disorders, liver and kidney dysfunction, or any other diseases and physiological conditions that may affect the study results at screening;
  13. Screening or baseline 12-lead with interval ≥ 450 ms (males), QTcF interval ≥ 460 ms (females); or ECG abnormal and considered abnormal and clinically significant by the investigator;
  14. Laboratory test results during screening period or baseline period meet the following abnormal range requirements and are considered abnormal and clinically significant by the investigator:

    1. Abnormal liver function: (ALT) or aspartate aminotransferase (AST)≥;
    2. Abnormal coagulation function: (APTT) or international normalized ratio (INR) ≥ULN;
    3. Abnormal thyroid function: Free triiodothyronine (FT3) or free thyroxine (FT4) or thyroid stimulating hormone (TSH) higher than ULN;
  15. Subjects with surface antigen quantitative determination positive, antibody quantitative determination positive, antigen antibody determination positive or treponema pallidum antibody determination positive at screening period or baseline period;
  16. Have special requirements for diet and fail to comply with the diet and corresponding regulations provided by the clinical trial institution;
  17. Those who cannot control special diet (including pitaya, mango, grapefruit and/or xanthine diet, caffeine-containing food or beverage, etc.) during the trial;
  18. Strenuous exercise within 48 hours prior to the first dose, or planned strenuous exercise during the trial;
  19. Regular drinkers within 6 months or during the trial, i.e. drinking more than 21 units of alcohol (male) or 14 units of alcohol (female) per week (1 unit =360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or unable to stop drinking during the trial, or positive alcohol breath test at baseline;
  20. Smoking more than 5 cigarettes per day in the 3 months, or using any tobacco products during the trial;
  21. Pregnant or lactating women or those with positive blood pregnancy test results;
  22. Subjects who have used long-acting estrogen or progesterone injection or implant tablets within 6 months or during the trial;
  23. Women of childbearing age who have had unprotected sex with their partners within 14 days prior to screening;
  24. Male or female subjects of do not agree to use an effective method of from the time of signing until 6 months after the last dose (see Section 10.3 for details of specific methods of contraception);
  25. Sperm or egg donation or fertility planning within 6 months from signing the informed consent form to the last dose;
  26. Vulnerable subjects such as the investigator himself/herself, relevant personnel of the study site and their family members, students and subordinates of the investigator, and employees of the sponsor;
  27. Any other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction (DDI) with Itraconazole and Ticagrelor

    Subjects will take AL3818 8 mg orally in fasted condition on D1, D29 and D58 together with itraconazole or ticagrelor for a convenience. Subjects are prohibited from eating and drinking for 4 h before dosing and for 4h after dosing. Water is prohibited from 1 h before dosing to 1 h after dosing, except for water administered to subjects. Meal may be eaten 4 hours after dosing and subjects should be dosed at approximately the same time as eating each day. Subjects will take itraconazole capsule 400 mg orally in D26 and take itraconazole capsule 200mg QD orally from D27 to D39 for 14 consecutive days at approximately the same time each day. Subjects will take ticagrelor tablet 90 mg orally twice daily, once in the morning and once in the evening for 4 consecutive days from D57 to D60.

    Drug: AL3818 Capsule · Drug: Itraconazole capsule · Drug: Ticagrelor Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameters of AL3818 include

    Cmax

    Time frame: through study completion, an average of 1 year

  2. PK parameters of AL3818 include

    AUC0-t

    Time frame: through study completion, an average of 1 year

  3. PK parameters of AL3818 include

    AUC0-∞

    Time frame: through study completion, an average of 1 year

  4. PK parameters of AL3818 include

    Tmax

    Time frame: through study completion, an average of 1 year

  5. PK parameters of AL3818 include

    λz

    Time frame: through study completion, an average of 1 year

  6. PK parameters of AL3818 include

    t1/2z

    Time frame: through study completion, an average of 1 year

  7. PK parameters of AL3818 include

    Vz/F

    Time frame: through study completion, an average of 1 year

  8. PK parameters of AL3818 include

    CL/F

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Beijing GoBroad Hospital Ethics Review Committee
    Beijing, Beijing Municipality 102200, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 27, 2026
StartEst.
Mar 2, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07438886
Lead sponsor
Advenchen Laboratories Nanjing Ltd.
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 2, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Qing He
Contact
heq@gobroadhealthcare.com
13358112136
Qing He
principal investigator · Beijing GoBroad Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anlotinib · Itraconazole · Ticagrelor

Start the discussion